Compare Domino's Pizza, Inc. (DPZ) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Domino's Pizza, Inc. vs Mesoblast Limited — how do they compare? Domino's Pizza, Inc. trades at $309.87 (market cap $10.21B), while Mesoblast Limited trades at $13.8 (market cap $1.75B). The key difference: Domino's Pizza, Inc. is far larger — about 5.8× Mesoblast Limited's market cap, and Domino's Pizza, Inc. pays a 2.58% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Domino's Pizza, Inc. for 106 Days and Mesoblast Limited for 14 Days on average.
| DPZ | MESO | |
|---|---|---|
Market Cap | $10.21B | $1.75B |
Volume | 916,737 | 239,027 |
Sector | Consumer Cyclical | Health |
52-Week High | $438.42 | $20.96 |
52-Week Low | $282.89 | $13.19 |
Typical Hold Time | 106 Days | 14 Days |
Enterprise Value | $15.17B | $1.83B |
Dividend Yield | 2.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Domino's Pizza (DPZ) trades at $303.10, showing minimal daily movement with a 0.08% gain. The stock faces technical headwinds with bearish moving averages and overbought RSI signals, while recent earnings misses and high debt levels of $5.7 billion create fundamental concerns. However, analyst sentiment remains positive with a $373 consensus price target representing 23% upside potential, supported by consistent revenue growth and strong profitability margins.
The outlook balances strong cash flow generation and market leadership against significant leverage and recent earnings disappointments. Investment opportunity exists in the valuation discount to analyst targets, but risks include debt servicing costs, competitive pressures, and execution challenges in maintaining growth momentum amid economic uncertainty.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
